Skip to main content
. 2021 Mar 27;276:119376. doi: 10.1016/j.lfs.2021.119376

Table 1.

Baseline characteristics of COVID-19 patients.

Characteristics COVID-19 patients (n = 20) Critical COVID-19 (n = 10) Mild-to-severe COVID-19 (n = 10) p value
Demographic
Age (years), median IQR 57 (50–70) 57 (50–70) 59 (47–71) 0.94
Male gender (%) 48% 70% 30% 0.08
Female gender (%) 52% 30% 70% 0.08



Comorbidities
Hypertension (%) 65% 70% 60% 0.68
Heart disease 50% 40% 30% 0.68
Diabetes (%) 45% 30% 70% 0.20
Obesity (%) 50% 30% 70% 0.09
BMI, median, IQR 28 (25–35) 27.7 (25–31) 31.3 (24–42) 0.72



Clinical characteristics
Days of symptoms (mean, ±sd) 13 ± 5 13 ± 4 13 ± 6 0.82
Hospitalization (days), mean, ±sd 18 ± 11 26 ± 11 11 ± 4 0.0004
Mechanical ventilation (%) 50% 100% 0 0.0001
Acute kidney injury (%) 35% 50% 20% 0.185
Mortality rate (%) 10% 20% 0 0.0001



Laboratory tests
Creatinine, mg/dl, mean (IQR) 1.1 ± 0.9 1.23 ± 1.34 0.94 ± 0.47 0.85
Lymphocyte; mm3, median (IQR) 1100 (600–1650) 650 (475–1550) 1295 (975–2450) 0.09
Platelets; ×103/l (IQR) 246 (217–338) 251 (218–369) 243 (186–313) 0.85
RCP; mg/dl, median (IQR) 13 (9–20) 10.8 (6.9–14.1) 7.1 (1.9–13.3) 0.23
D dimer; mg/dl, median (IQR) 1.19 (0.93–1.98) 1.3 (1–3.5) 1 (0.8–1.7) 0.43
Lactate; mg/dl, median (IQR) 2.2 (1.7–2.6) 2.5 (2–2.6) 1.7 (1.5–2.5) 0.09
Lactate dehydrogenase, U/l(IQR) 361 (302–434) 340 (292–438) 383 (278–498) 0.89
Ferritin, ng/ml (IQR) 608 (345–1076) 608 (246–635) 600 (345–1409) 0.51
Fibrinogen (mg/dl) 686 (619–815) 796 (619–833) 683 (617–799) 0.55



Severity
PaO2/FiO2 ratio, median (IQR) 205 (139–315) 158 (122–194) 272 (211–358) 0.01
SOFA score 2 (1–3) 3 (2–4.5) 2 (1–2) 0.005
SAPS-3 47 (38–50) 47 (42–51) 42 (34–47) 0.11

BMI: body mass index; IQR: interquartile range; sd: standard deviation; RCP: reactive C protein; PaO2/FiO2 ratio: the ratio of arterial oxygen partial pressure (PaO2 in mm Hg) to fractional inspired oxygen; SOFA: sequential organ failure assessment; SAPS-3: simplified acute physiology score III.

p < 0.05, comparison between mild-to-severe and critical patients with COVID-19.